Filter posts

Biomedical R&D in the 21st Century

Reflecting back upon my career,  I recognize the importance academic-industry research partnerships played in shaping …

#BIO 2013: Open Innovation and Biopharmaceutical R&D

In these changing times, the concept of Open Innovation is one that we at AstraZeneca …

Q & A with Eli Lilly’s Eric Siemers

In October 2012, Eli Lilly and Company released results of its Expedition trials, two Phase …

New Challenges in the Fast Changing Landscape of Bioinformatics

The world of DNA sequencing and bioinformatics has evolved at a staggering pace. In 2009, …

Worldwide Orphan Drug Market to Grow to $127 Billion by 2018

The 2013 Orphan Drug Report from Evaluate, which launched today at the 2013 BIO international …

Expanding Access to Orphan Drugs

At present many orphan diseases do not have any licensed treatments, and for those conditions …

Our Health Care Ecosystem

There are currently 907 drugs and vaccines targeting more than 100 diseases in development by …

Approving Drugs for Alzheimer’s Disease

BIOtechNOW delves into the current state of Alzheimer’s disease research with today’s feature on regulatory …

Patients are the Missing Link in R&D

An architect does not wait until construction begins to show clients a blueprint. Neither does a caterer …

Cranial Connections: Ontario’s Brain Research is Hardwired for Success

Ontario has long been a leader in life sciences research and technology with brain exploration …